Page 15 - MSC手冊 20220831

COVID-19

肺損傷 & 急性呼吸窘迫症候群

使用臍帶間質幹細胞(MSC)治療COVID-19急性呼吸窘迫症候群，
1個月後的存活率高達91%

Received: 23 October 2020 Accepted: 6 December 2020
DOI: 10.1002/sctm.20-0472
HU MA N C LINICA L A RTICLE

Umbilical cord mesenchymal stem cells for COVID-19 acute
respiratory distress syndrome: A double-blind, phase 1/2a,

randomized controlled trial

Giacomo Lanzoni 1,2 | Elina Linetsky 1,3 | Diego Correa 1,4 |
6,7
5
1
˙ 實驗作法：治療組的患者3天內2度被輸注了1X10 個細胞，合計每人共接受了2X10 8
| Roger A. Alvarez
| Dimitrios Kouroupis
|
Shari Messinger Cayetano
8
| Raffaella Poggioli
Ana Alvarez Gil 1 個細胞。 1 | Phillip Ruiz 3 | Antonio C. Marttos 6,7,8 |
Khemraj Hirani 1,6 | Crystal A. Bell 6 | Halina Kusack 6 | Lisa Rafkin 1 |
˙ 實驗結果：幹細胞治療組的患者1個月後的存活率高達91%，而接受安慰劑治療的
David Baidal 1,6,7 | Andrew Pastewski 8 | Kunal Gawri 6,7 | Clarissa Leñero 1 |
對照組
5
1
1
| Sarah W. Metalonis
| Xiaojing Wang
|
Alejandro M. A. Mantero 5則僅為 42%，其中年齡小於85歲的患者中，接受幹細胞治療者
| Luis Roque
Burlett Masters1個月後存活率高 1 | Enrique Ginzburg 3,7,8 | Xiumin Xu 1 |
| Norma S. Kenyon100%。
1
9
10
11
| Arnold I. Caplan
Jianming Tan
|
| Marilyn K. Glassberg
˙ 此外，研究人員更發現，這項治療相當安全，並沒有發生任何與輸液有關的嚴重不良事件。
Rodolfo Alejandro 1,6,7 | Camillo Ricordi 1,3
1 Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida
2 Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida
91%
3 Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida
4 100% — 80%
Department of Orthopedics, UHealth Sports Medicine Institute, University of Miami Miller School of Medicine, Miami, Florida
5 Division of Biostatistics, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida
6 Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida
42%
50% —
7 University of Miami Health System, Miami, Florida 37%
8 Jackson Health System, Miami, Florida
9 The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, People's Republic of China
10 Skeletal Research Center, Case Western Reserve University, Cleveland, Ohio
0%
11 University of Arizona College of Medicine, Tucson, Arizona
重症症患者存活率 ㄧ個月後康復痊癒
Correspondence ■對照組 ■治療組
Camillo Ricordi, MD, Diabetes Research Abstract
Institute, Cell Transplant Center, University of Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality.
Miami Miller School of Medicine, 1450 NW
Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory
10th Ave., Miami, FL 33137, USA.
資料來源：Stem Cells Transl Med. 2021 May;10(5):660-673 13
Tel +1 305 582 7151; FAX +1 305 243 4404 effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study
Email: ricordi@miami.edu
was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-
Funding information MSC) infusions in subjects with COVID-19 ARDS. A double-blind, phase 1/2a, randomized,
National Center for Advancing Translational
Sciences, Grant/Award Numbers: controlled trial was performed. Randomization and stratification by ARDS severity was used
UL1TR002736, UL1TR000460; Ugo Colombo; to foster balance among groups. All subjects were analyzed under intention to treat design.
Simkins Family Foundation; Fondazione Silvio
Tronchetti Provera; Barilla Group and Family; Twenty-four subjects were randomized 1:1 to either UC-MSC treatment (n = 12) or the
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press
660 wileyonlinelibrary.com/journal/sct3 STEM CELLS Transl Med. 2021;10:660–673.